Company Valuation: Provectus Biopharmaceuticals, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 23.43 23.07 45.43 40.27 50.48 23.49
Change - -1.55% 96.93% -11.35% 25.33% -53.46%
Enterprise Value (EV) 1 47.13 24.13 47.59 43.22 53.35 26.22
Change - -48.8% 97.24% -9.18% 23.43% -50.85%
P/E -3.44x -4.05x -12.8x -13x -10.6x -4.33x
PBR -0.77x -5.48x -7.27x -5.29x -8.45x -3.72x
PEG - 0.2x 0.3x 1x -0.2x -0.3x
Capitalization / Revenue - - 4,59,34,892x 7,22,13,378x 8,17,89,566x 6,98,99,095x
EV / Revenue - - - - - -
EV / EBITDA -10x -5.21x -14.1x -17.4x -13.5x -5.41x
EV / EBIT -9.55x -5.2x -14x -17.3x -13.5x -5.41x
EV / FCF 44.5x -3.48x -39.6x -37.2x -18.2x -19.6x
FCF Yield 2.25% -28.8% -2.53% -2.68% -5.5% -5.1%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -0.017 -0.0136 -0.008474 -0.007393 -0.0113 -0.0129
Distribution rate - - - - - -
Net sales - - 0.989 0.5577 0.6171 0.3361
EBITDA 1 -4.694 -4.628 -3.38 -2.489 -3.939 -4.842
EBIT 1 -4.936 -4.641 -3.391 -2.498 -3.946 -4.844
Net income 1 -6.678 -5.54 -3.555 -3.102 -4.762 -5.431
Net Debt 1 23.7 1.061 2.163 2.95 2.877 2.727
Reference price 2 0.0584 0.0550 0.1083 0.0960 0.1201 0.0559
Nbr of stocks (in thousands) 4,01,232 4,19,447 4,19,497 4,19,522 4,20,280 4,20,280
Announcement Date 02/03/21 29/03/22 30/03/23 28/03/24 28/03/25 26/03/26
1USD in Million2USD
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
21.73x7.71x15.48x1.37% 7.42TCr
29.82x8.57x26.7x0.04% 5.74TCr
32.98x5.93x17.77x0.98% 4.76TCr
-21.31x230.81x-22.97x-.--% 4.43TCr
33.26x3.23x13.97x-.--% 4.25TCr
46.77x5.41x29.66x-.--% 4.07TCr
27.63x7.93x20.48x0.41% 3.1TCr
32.99x7.05x18.3x-.--% 2.85TCr
-15.1x5.68x-7.14x-.--% 2.43TCr
Average 20.98x 31.37x 12.47x 0.31% 4.34TCr
Weighted average by Cap. 22.27x 32.04x 13.55x 0.42%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. PVCT Stock
  4. PVCT Stock
  5. Valuation Provectus Biopharmaceuticals, Inc.